Capital Bank & Trust’s Novartis NVS Stock Holding History

Capital Bank & Trust’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,423	Closed	-$117K	–	531
2020 Q1	$117K	Sell	1,423 -436	-23%	-$38.9K	﹤0.01%	333
2019 Q4	$176K	Sell	1,859 -39	-2%	-$3.5K	﹤0.01%	314
2019 Q3	$165K	Sell	1,898 -55,289	-97%	-$4.96M	﹤0.01%	314
2019 Q2	$5.2M	Sell	57,187 -3,155	-5%	-$267K	0.06%	145
2019 Q1	$5.17M	Buy	60,342 +2,906	+5%	+$233K	0.07%	146
2018 Q4	$4.42M	Buy	57,436 +4,499	+8%	+$350K	0.06%	142
2018 Q3	$4.09M	Buy	52,937 +4,980	+10%	+$368K	0.05%	150
2018 Q2	$3.25M	Buy	47,957 +1,114	+2%	+$76.9K	0.04%	154
2018 Q1	$3.39M	Buy	46,843 +1,473	+3%	+$112K	0.05%	148
2017 Q4	$3.41M	Sell	45,370 -108,869	-71%	-$8.21M	0.05%	151
2017 Q3	$11.9M	Buy	154,239 +8,036	+5%	+$607K	0.15%	119
2017 Q2	$10.9M	Buy	+146,203	New	+$10.4M	0.14%	124

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Capital Bank & Trust's NVS Position: Q2 2020 in Review

Capital Bank & Trust sold out of Novartis (NVS) in Q2 2020, closing a stake of 1,423 shares — an estimated $117K sold.

Capital Bank & Trust first reported a position in NVS in Q2 2017 and held it in 12 quarters. The position peaked at $11.9M in Q3 2017. 1,128 funds tracked by Wall St. Rank hold NVS as of Q2 2020.

Capital Bank & Trust reported no remaining Novartis position as of Q2 2020 after selling out during the quarter.
Capital Bank & Trust sold 1,423 Novartis shares in Q2 2020, an estimated $117K.
Capital Bank & Trust first reported a position in Novartis in Q2 2017 and held it in 12 quarters.
Capital Bank & Trust's Novartis position peaked at $11.9M in Q3 2017.
1,128 funds tracked by Wall St. Rank held Novartis as of Q2 2020.

Based on Capital Bank & Trust's 13F filing for Q2 2020, filed 14 Aug 2020.